ChromaDex Opens New State-of-the-Art Research and

IRVINE, Calif., Jan. 05, 2017 (GLOBE NEWSWIRE) -- Today, ChromaDex Corporation ( https://www.chromadex.com/ )  (NASDAQ: CDXC ), an innovator of proprietary health, wellness and nutritional ingredients that creates science-based solutions for dietary supplement, food and beverage, skin care, sports nutrition, and pharmaceutical products, is announcing the official grand opening of its new 10,000-square-foot research and development center in Longmont, Colorado.

With nearly $1 million invested to renovate the space into a state-of-the-art facility, it now includes multiple laboratories which will support the discovery and development of novel molecules and compounds to add to ChromaDex’s proprietary ingredient portfolio, while also allowing for the expansion of ChromaDex’s analytical service offerings at its Boulder, Colorado, location.

The grand opening ceremony will be held today, Thursday, January 5 ^th , with Longmont Mayor, Dennis L. Coombs, as well as members from the Longmont Economic Development Partnership and ChromaDex Corporation in attendance.

Chief Operating Officer, Troy Rhonemus commented, “The construction and opening of the Longmont R&D facility marks an important growth milestone for ChromaDex. This facility is a critical asset that will enable us to acquire additional ingredient intellectual property, and continue our leadership in the identification and development of additional NAD+ metabolites.”

Nicotinamide adenine dinucleotide (NAD+) is an essential coenzyme in cellular metabolism. Published research suggests that many aging-related health challenges are linked to NAD+ deficiency.  NAD+ and its metabolites such as NR have been the focus of intense scientific research and popular news media coverage recently due to their believed roles in healthy aging and healthspan.  NR has been shown to safely and effectively increase NAD+ in humans supported by published research in Nature Communications.

ChromaDex, being publicly traded on NASDAQ, gives the public an opportunity for investing in the business of science-based technologies for healthy aging and longevity. To date, ChromaDex has invested millions in safety, toxicology and human clinical trials on NR. It has also has initiated over 100 collaborative studies with leading universities and research institutions such as the National Institute of Aging, MIT and the Scripps Research Institute representing an estimated $40-50 million in NR research.  Most of ChromaDex’s recent revenue growth has come from its proprietary ingredients, in particular NIAGEN ^® , which is commercially manufactured NR by ChromaDex.

Frank Jaksch Jr., Founder and CEO of ChromaDex, stated, “These collaborative studies are a huge validation that NR is very much relevant to the research community, as many of these collaborations that started as preclinical animal studies are now being published in top tier peer-reviewed journals such as Nature, Science and Cell Metabolism. We are now moving into human clinical studies based on the preclinical success of NR.” 

ChromaDex’s current proprietary ingredient portfolio is backed with clinical and scientific research, as well as extensive IP protection. In addition to NIAGEN ^® , NR, ChromaDex also has pTeroPure ^® pterostilbene; PURENERGY ^® , a caffeine-pTeroPure ^® co-crystal; IMMULINA ^™ , a spirulina extract; and AnthOrigin ^™ , naturally extracted anthocyanins, in its portfolio of patented technologies.

For more information on ChromaDex, visit: https://www.chromadex.com/ .

About ChromaDex: ChromaDex leverages its complementary business units to discover, acquire, develop and commercialize patented and proprietary ingredient technologies that address the dietary supplement, food, beverage, skin care and pharmaceutical markets. In addition to our ingredient technologies unit, we also have business units focused on natural product fine chemicals (known as "phytochemicals"), chemistry and analytical testing services, and product regulatory and safety consulting (known as Spherix Consulting). As a result of our relationships with leading universities and research institutions, we are able to discover and license early stage, IP-backed ingredient technologies. We then utilize our in-house chemistry, regulatory and safety consulting business units to develop commercially viable ingredients. Our ingredient portfolio is backed with clinical and scientific research, as well as extensive IP protection. Our portfolio of patented ingredient technologies includes NIAGEN ^® nicotinamide riboside; pTeroPure ^® pterostilbene; PURENERGY ^® , a caffeine-pTeroPure ^® co-crystal; IMMULINA ^™ , a spirulina extract; and AnthOrigin™, anthocyanins derived from a domestically-produced, water-extracted purple corn. To learn more about ChromaDex, please visit www.ChromaDex.com .

Forward-Looking Statements: This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended, including statements related to the asset’s ability to support the discovery and development of new molecules, ingredients and intellectual property. Statements that are not a description of historical facts constitute forward-looking statements and may often, but not always, be identified by the use of such words as "expects", "anticipates", "intends", "estimates", "plans", "potential", "possible", "probable", "believes", "seeks", "may", "will", "should", "could" or the negative of such terms or other similar expressions. More detailed information about ChromaDex and the risk factors that may affect the realization of forward-looking statements is set forth in ChromaDex's Annual Report on Form 10-K for the fiscal year ended January 2, 2016, ChromaDex's Quarterly Reports on Form 10-Q and other filings submitted by ChromaDex to the SEC, copies of which may be obtained from the SEC's website at www.sec.gov . Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and actual results may differ materially from those suggested by these forward-looking statements. All forward-looking statements are qualified in their entirety by this cautionary statement and ChromaDex undertakes no obligation to revise or update this release to reflect events or circumstances after the date hereof.                                                                      

ChromaDex Public Relations Contact: Breah Ostendorf, Director of Marketing 949-537-4103 breaho@chromadex.com ChromaDex Investor Relations Contact: Andrew Johnson, Director of Investor Relations 949-419-0288 andrewj@chromadex.com